Neuro_Bio_Group

Company Background

  • 2002: Identified the possible pivotal toxin in Alzheimer’s Disease.
  • 2004: Identified the target of the toxin.
  • 2004 – 2012: Characterised bioactivity of toxin and designed blocker.
  • 2013: Negotiated with University, IP assigned Neuro-Bio

Company Development 2013 – 2017

2013

2013

Formed the company and attracted initial seed investment.


2013

2013

Filed patent application on chemical copostition of matter for neuro-protection.


2014

2014

Attracted angel funding, recruited scientific team and established own labs.


2015/2016

2015/2016

Filed patent on biomarker and identified direct link with Alzheimer’s.


2016

2016

Attracted Series A funding, recruited management team and identified drug and biomarker development partners.